From the 31 patients with CD (mean age: 14.1 ± 2.6 years, 19 males), 20 (65%) were newly diagnosed and 11 (35%) were starting anti-TNF therapy due to refractoriness to conservative therapy according to the guidelines at the time of the BC assessment (24, 25). The gene discussed is TNF; the disease is breast cancer.